3/4
01:11 pm
ghrs
GH Research PLC (NASDAQ: GHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
GH Research PLC (NASDAQ: GHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
3/1
12:39 pm
ghrs
GH Research PLC (NASDAQ: GHRS) had its price target lowered by analysts at JMP Securities from $50.00 to $39.00. They now have a "market outperform" rating on the stock.
Medium
Report
GH Research PLC (NASDAQ: GHRS) had its price target lowered by analysts at JMP Securities from $50.00 to $39.00. They now have a "market outperform" rating on the stock.
2/29
07:23 am
ghrs
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
2/29
07:00 am
ghrs
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
Medium
Report
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
1/18
04:46 pm
ghrs
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression [Yahoo! Finance]
Low
Report
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression [Yahoo! Finance]
1/18
04:30 pm
ghrs
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
Medium
Report
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression